SUPRAX (cefixime) by Pfizer is [see microbiology ( )] . First approved in 1989.
Drug data last refreshed 3d ago
SUPRAX (cefixime) is an oral third-generation cephalosporin antibiotic approved in 1989 for treating bacterial infections including gonorrhea, typhoid fever, bacterial vaginitis, and cervicitis. It works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism. The drug is available as an oral tablet formulation.
As LOE approaches, commercial infrastructure is likely contracting; positions increasingly focused on generic transition management and niche indication preservation rather than growth initiatives.
[see Microbiology ( )] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
Cefixime for Alternative Syphilis Treatment
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions
Cefixime / Azithromycin pK Study
Worked on SUPRAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SUPRAX offers limited career growth due to LOE-approaching lifecycle and minimal linked job opportunities (0 recorded). Positions emphasize operational efficiency, generic transition planning, and niche market defense rather than innovation or team expansion.